Malignant Urinary System Neoplasm — Trials

Malignant Urinary System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 887
Recruiting: 467
Ph III recruiting: 52
Growth YoY: +12.2%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.8%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (556)

clinicaltrialsPublishedShowing 151–200 of 427 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05501054	Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.	active not recruiting	Phase 1 / Phase 2	50	M.D. Anderson Cancer CenterOTHER	1	Jul 16, 2026	clinicaltrials
NCT05775471	Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer	recruiting	Phase 2	21	Jonsson Comprehensive Cancer CenterOTHER	1	Jul 16, 2026